Investor Presentation

2020 & 2019 Reconciliation EBITDA to Adjusted EBITDA Reconciliation of GAAP Net Income to Adjusted EBITDA (Unaudited, amounts in thousands) GAAP Net Income Adjustments Investment Income Interest expense Tax Provision Depreciation Intangible amortization EBITDA Other Adjustments Acquisition and integration costs Loss on extinguishment of debt Inventory step-up charges Adjusted EBITDA $ $ $ $ $ $ $ $ $ $ $ Twelve Months Ended December 31, 2020 59,926 (1,741) 12,133 (709) 10,888 16,143 96,640 10,479 734 107,853 $ $ Ś $ $ $ $ $ $ $ $ 2019 21,411 (5,324) 9,292 4,740 7,317 13,551 50,987 13,008 5,650 1,483 71,128 RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING 33

View entire presentation